Once integration is completed, the partners plan to accelerate commercial rollout across India, anticipated in 2026.

Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, is making progress in gaining broad access to Medicare reimbursement for its Epi+Gen CHD™ and ...

One of the strongest predictors of long-term mortality among patients undergoing a cardiac stress test is the need for a pharmacologic versus treadmill test, new data show. Moreover, although the risk ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch ...

Cardio Diagnostics Holdings will partner with a longtime distribution leader in India and an Indian network of nearly 300 ...

Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS) The final gapfill payment rate for both the Epi+Gen ...

Beth Skwarecki is Lifehacker’s Senior Health Editor and has been writing about health, fitness, and science here since 2015. Beth was the recipient of the 2017 Carnegie Science Award in science ...

Plenty of research touts the importance of cardiorespiratory fitness (CRF)—also known as cardio fitness, cardiovascular endurance, and aerobic fitness—as a health marker, as well as an athletic ...